Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma.
Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma.
复制标题
DOI：
10.1002/lt.22340
复制
发表时间：
2011-10
影响因子：
4.6
通讯作者：
Zucman-Rossi, Jessica
中科院分区：
文献类型：
--
作者：
Llovet, Josep M.;Paradis, Valerie;Kudo, Masatoshi;Zucman-Rossi, Jessica
肝细胞癌（HCC）是世界范围内癌症死亡的常见原因，其年发病率呈上升趋势。肝移植（LT）是一种可接受的治愈性治疗符合米兰标准（单个肿瘤直径5 cm或多达3个肿瘤，每个直径3 cm，无大血管浸润）的肿瘤患者。这些标准预测LT后的总体5年生存率为70%。1自从米兰标准引入以来，随后的研究探索了移植受体选择的扩展，以包括肿瘤超过米兰标准的个体。2最近的一项研究表明，在没有微血管浸润的情况下，对于那些接受移植治疗的肿瘤患者，超过米兰标准但满足最多7规则（7是最大肿瘤的厘米大小和肿瘤数量之和）的患者，总体5年生存率可接受（71.2%）。3这种方法是基于可用于理解LT后肿瘤行为的最佳数据，但它仍然基于病理学数据。肿瘤大小和肿瘤数量不能用于定义具有更好生物学和更好结果的患者亚类，因此生物标志物有望在未来十年内成为这一领域的重要一步。已经确定了许多参与HCC发病机制的分子途径。这些包括参与血管生成[血管内皮生长因子（VEGF）]、细胞增殖和存活（表皮生长因子、胰岛素样生长因子和肝细胞生长因子/Met）以及细胞分化和增殖（Wnt/b-连环蛋白和hedgehog信号传导）的激活途径。激活缩写：AFP，甲胎蛋白; Ang 2，血管生成素2; HCC，肝细胞癌; LT，肝移植; miRNA，微小RNA; mRNA，信使RNA;备注，肿瘤标志物预后研究的报告建议; VEGF，血管内皮生长因子。
Hepatocellular carcinoma (HCC) is a common cause of cancer deaths worldwide, and its annual incidence is rising. Liver transplantation (LT) is an accepted curative treatment for patients with tumors satisfying the Milan criteria (a single tumor 5 cm in diameter or up to 3 tumors with individual diameters 3 cm and no macrovascular invasion). These criteria predict an overall 5-year survival rate of 70% after LT. 1 Since the introduction of the Milan criteria, subsequent studies have explored the expansion of transplant recipient selection to include individuals with tumors exceeding the Milan criteria. 2 A recent study demonstrated an acceptable overall 5-year survival rate (71.2%) for patients who underwent transplantation for tumors that were beyond the Milan criteria but satisfied the up-to-7 rule (7 is the sum of the size of the largest tumor in centimeters and the number of tumors) in the absence of microvascular invasion. 3 This approach is based on the best data available for understanding tumor behavior after LT, but it is still based on pathological data. The tumor size and the tumor number cannot be used to define subclasses of patients with better biology and better outcomes, so biomarkers are expected to be a major step forward in this setting during the next decade. Numerous molecular pathways involved in the pathogenesis of HCC have been identified. These include activation pathways that are involved in angiogenesis [vascular endothelial growth factor (VEGF)], in cell proliferation and survival (epidermal growth factor, insulin-like growth factor, and hepatocyte growth factor/Met), and in cell differentiation and proliferation (Wnt/b-catenin and hedgehog signaling). The activation ofAbbreviations: AFP, alpha-fetoprotein; Ang2, angiopoietin 2; HCC, hepatocellular carcinoma; LT, liver transplantation; miRNA, microRNA; mRNA, messenger RNA; REMARK, Reporting Recommendations for Tumor Marker Prognostic Studies; VEGF, vascular endothelial growth factor.
登录
查看更多内容
影响因子：
4.2
作者：
Hoshida Y;Toffanin S;Lachenmayer A;Villanueva A;Minguez B;Llovet JM
通讯作者：
Llovet JM
影响因子：
13.5
作者：
Llovet, Josep M.;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
29.4
作者：
Laurent-Puig, P;Legoix, P;Zucman-Rossi, J
通讯作者：
Zucman-Rossi, J
影响因子：
9.6
作者：
Poon, RTP;Ho, JWY;Fan, ST
通讯作者：
Fan, ST
影响因子：
13.5
作者：
Nam, SW;Park, JY;Lee, JY
通讯作者：
Lee, JY